|
Relationship between fibroblast growth factor-23 in peripheral blood and cardiovascular events in maintenance hemodialysis patients
LI Kai-long;CHEN Jing;ZHANG Ying;WANG Yan;LI Kai-bin;HE Ya-ni
2011, 10 (4):
194-197.
doi: 10.3969/j.issn.1671-4091.2011.04.00
【Abstract】 Objective To study the relationship between fibroblast growth factor-23 (FGF-23) in peripheral blood and cardiovascular complications in patients on maintenance hemodialysis (MHD). Methods A total of 155 patients with chronic kidney disease (CKD) at stage 5 treated in this hemodialysis center from Oct. 2006 to Feb. 2010 were enrolled in the study, and the study was lasted for 6 months. Patients were divided into cardiovascular event group or non-cardiovascular event group. The 2 groups were compared in gender, age, primary disease for CKD, blood pressure control, hemoglobin level, nutritional status, dialysis modality and drugs used. Serum phosphorus (P), calcium (Ca), intact parathyroid hormone (iPTH), FGF-23 and plasma 1,25(OH)2D3 levels were determined before and after the study. Results FGF-23 levels in peripheral blood were significantly higher in cardiovascular event group than in non-cardiovascular event group (P<0.001). Correlation analysis indicated that the FGF-23 levels in peripheral blood correlated significantly with the cardiovascular events in MHD patients (P<0.001). Hemofiltration (HF) time was obviously longer in non-cardiovascular event group than in cardiovascular event group (P< 0.001). In non-cardiovascular event group, serum P, iPTH, and FGF-23 were lower at the end of the study, as compared with those at the beginning of the study (P< 0.001). At the end of the study, serum P, iPTH, and FGF-23 also reduced in cardiovascular event group, as compared with those in non-cardiovascular event group (P< 0.001). Conclusion FGF23 levels in peripheral blood correlate significantly with cardiovascular events in MHD patients, suggesting that FGF-23 level in peripheral blood may be used as an early warning indicator for cardiovascular events in MHD patients. HF has the better abilities to excrete P, iPTH and FGF-23. Hemodialysis combined with HF effectively reduce the cardiovascular events in MHD patients.
Metrics
|